148 related articles for article (PubMed ID: 3736880)
1. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease.
Bhaskar PA; Vanchilingam S; Bhaskar EA; Devaprabhu A; Ganesan RA
Neurology; 1986 Aug; 36(8):1119-21. PubMed ID: 3736880
[TBL] [Abstract][Full Text] [Related]
2. Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
Sollazzo D
Electroencephalogr Clin Neurophysiol; 1985 Oct; 61(4):236-42. PubMed ID: 2411501
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
Cosi V; Romani A; Callieco R; Zerbi F
Boll Soc Ital Biol Sper; 1984 Mar; 60(3):603-9. PubMed ID: 6712828
[TBL] [Abstract][Full Text] [Related]
4. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials.
Peppe A; Stanzione P; Pierelli F; De Angelis D; Pierantozzi M; Bernardi G
Neurology; 1995 Jun; 45(6):1144-8. PubMed ID: 7783879
[TBL] [Abstract][Full Text] [Related]
5. Visual evoked potentials (VEPs) in Parkinson's disease: correlation of pattern VEPs abnormality with dementia.
Okuda B; Tachibana H; Kawabata K; Takeda M; Sugita M
Alzheimer Dis Assoc Disord; 1995; 9(2):68-72. PubMed ID: 7662325
[TBL] [Abstract][Full Text] [Related]
6. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Onofrj M; Ghilardi MF; Basciani M; Gambi D
J Neurol Neurosurg Psychiatry; 1986 Oct; 49(10):1150-9. PubMed ID: 3023551
[TBL] [Abstract][Full Text] [Related]
7. Measurements of visual evoked potentials in Parkinson's disease.
Bodis-Wollner I; Yahr MD
Brain; 1978 Dec; 101(4):661-71. PubMed ID: 737524
[TBL] [Abstract][Full Text] [Related]
8. [Cortical and spinal evoked potentials in parkinsonism. Part I. Visual potentials evoked with a checkerboard pattern].
Bieszczad M; Ejma M; Podemski R
Neurol Neurochir Pol; 1991; 25(1):7-14. PubMed ID: 2034336
[TBL] [Abstract][Full Text] [Related]
9. VEP changes in Parkinson's disease are stimulus dependent.
Tartaglione A; Pizio N; Bino G; Spadavecchia L; Favale E
J Neurol Neurosurg Psychiatry; 1984 Mar; 47(3):305-7. PubMed ID: 6707679
[TBL] [Abstract][Full Text] [Related]
10. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
[TBL] [Abstract][Full Text] [Related]
11. Speech changes in Parkinson's disease during treatment with L-dopa.
Wolfe VI; Garvin JS; Bacon M; Waldrop W
J Commun Disord; 1975 Sep; 8(3):271-9. PubMed ID: 802977
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of visual evoked potentials with dementia in Parkinson's disease].
Okuda B; Tachibana H; Kawabata K; Takeda M; Toda K; Sugita M
Nihon Ronen Igakkai Zasshi; 1992 Jun; 29(6):475-9. PubMed ID: 1527904
[TBL] [Abstract][Full Text] [Related]
13. Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Geng X; Wang X; Xie J; Zhang X; Wang X; Hou Y; Lei C; Li M; Han H; Yao X; Zhang Q; Wang M
Behav Brain Res; 2016 Dec; 315():1-9. PubMed ID: 27515286
[TBL] [Abstract][Full Text] [Related]
14. The Bereitschaftspotential, L-DOPA and Parkinson's disease.
Dick JP; Cantello R; Buruma O; Gioux M; Benecke R; Day BL; Rothwell JC; Thompson PD; Marsden CD
Electroencephalogr Clin Neurophysiol; 1987 Mar; 66(3):263-74. PubMed ID: 2434310
[TBL] [Abstract][Full Text] [Related]
15. L-dopa and the secretion of sebum in Parkinsonian patients.
Streifler M; Avrami E; Rabey JM
Eur Neurol; 1980; 19(1):43-8. PubMed ID: 7371653
[TBL] [Abstract][Full Text] [Related]
16. Dilemma in the treatment of Parkinson's disease with L-dopa.
Kuno S
Eur Neurol; 1994; 34 Suppl 3():17-9. PubMed ID: 7821330
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
18. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
20. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.
Peschanski M; Defer G; N'Guyen JP; Ricolfi F; Monfort JC; Remy P; Geny C; Samson Y; Hantraye P; Jeny R
Brain; 1994 Jun; 117 ( Pt 3)():487-99. PubMed ID: 8032859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
